ArticleFrontiers in pharmacology2017
Dihydromyricetin Protects against Bone Loss in Ovariectomized Mice by Suppressing Osteoclast Activity.
Article in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 22 citations in OpenAlex.
- Efficacy of 12-month romosozumab monotherapy or combination with eldecalcitol in patients with osteoporosis with and without chronic kidney disease: A real-world retrospective study.Biomedical reports · 2025Article
- The Mechanisms and Quality Markers of Anti-rheumatoid Arthritis of Traditional Chinese Medicine.Combinatorial chemistry & high throughput screening · 2025Review
- Dihydromyricetin ameliorate postmenopausal osteoporosis in ovariectomized mice: Integrative microbiomic and metabolomic analysis.Frontiers in pharmacology · 2024Article
- A Novel Inhibitor INF 39 Promotes Osteogenesis via Blocking the NLRP3/IL-1BioMed research international · 2022Article
- Recent advances in research on vine tea, a potential and functional herbal tea with dihydromyricetin and myricetin as major bioactive compounds.Journal of pharmaceutical analysis · 2021Review
- Up-regulated CST5 inhibits bone resorption and activation of osteoclasts in rat models of osteoporosis via suppression of the NF-κB pathway.Journal of cellular and molecular medicine · 2019Article
- Dihydromyricetin Ameliorates Cardiac Ischemia/Reperfusion Injury through Sirt3 Activation.BioMed research international · 2019Article
- Connexin 43 hemichannels protect bone loss during estrogen deficiency.Bone research · 2019Article
- Recent Update on the Pharmacological Effects and Mechanisms of Dihydromyricetin.Frontiers in pharmacology · 2018Review
- Effects of Taxifolin on OsteoclastogenesisFrontiers in pharmacology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dihydromyricetin (DMY), the main flavonoid component of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.